Compagnie Lombard Odier SCmA’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-112
| Closed | -$10K | – | 609 |
|
|
2021
Q4 | $10K | Hold |
112
| – | – | ﹤0.01% | 619 |
|
|
2021
Q3 | $9K | Hold |
112
| – | – | ﹤0.01% | 600 |
|
|
2021
Q2 | $9K | Hold |
112
| – | – | ﹤0.01% | 593 |
|
|
2021
Q1 | $8K | Hold |
112
| – | – | ﹤0.01% | 612 |
|
|
2020
Q4 | $10K | Hold |
112
| – | – | ﹤0.01% | 528 |
|
|
2020
Q3 | $9K | Hold |
112
| – | – | ﹤0.01% | 475 |
|
|
2020
Q2 | $14K | Hold |
112
| – | – | ﹤0.01% | 465 |
|
|
2020
Q1 | $9K | Hold |
112
| – | – | ﹤0.01% | 439 |
|
|
2019
Q4 | $9K | Hold |
112
| – | – | ﹤0.01% | 454 |
|
|
2019
Q3 | $8K | Hold |
112
| – | – | ﹤0.01% | 466 |
|
|
2019
Q2 | $10K | Sell |
112
-2,500
| -96% | -$214K | ﹤0.01% | 452 |
|
|
2019
Q1 | $232K | Buy |
2,612
+2,500
| +2,232% | +$232K | 0.01% | 277 |
|
|
2018
Q4 | $10K | Hold |
112
| – | – | ﹤0.01% | 482 |
|
|
2018
Q3 | $11K | Hold |
112
| – | – | ﹤0.01% | 510 |
|
|
2018
Q2 | $11K | Hold |
112
| – | – | ﹤0.01% | 546 |
|
|
2018
Q1 | $9K | Sell |
112
-112
| -50% | -$9.61K | ﹤0.01% | 552 |
|
|
2017
Q4 | $20K | Sell |
224
-688
| -75% | -$59.8K | ﹤0.01% | 578 |
|
|
2017
Q3 | $84K | Sell |
912
-3,050
| -77% | -$270K | ﹤0.01% | 462 |
|
|
2017
Q2 | $360K | Sell |
3,962
-2,000
| -34% | -$182K | 0.01% | 302 |
|
|
2017
Q1 | $524K | Sell |
5,962
-4,000
| -40% | -$356K | 0.02% | 281 |
|
|
2016
Q4 | $825K | Sell |
9,962
-11,500
| -54% | -$989K | 0.02% | 275 |
|
|
2016
Q3 | $1.99M | Sell |
21,462
-17,700
| -45% | -$1.67M | 0.06% | 186 |
|
|
2016
Q2 | $3.05M | Buy |
39,162
+25,106
| +179% | +$2.13M | 0.09% | 157 |
|
|
2016
Q1 | $1.16M | Buy |
14,056
+9,944
| +242% | +$809K | 0.04% | 239 |
|
|
2015
Q4 | $431K | Buy |
4,112
+4,000
| +3,571% | +$418K | 0.01% | 343 |
|
|
2015
Q3 | $12K | Hold |
112
| – | – | ﹤0.01% | 736 |
|
|
2015
Q2 | $15K | Hold |
112
| – | – | ﹤0.01% | 736 |
|
|
2015
Q1 | $14K | Hold |
112
| – | – | ﹤0.01% | 882 |
|
|
2014
Q4 | $10K | Sell |
112
-5,150
| -98% | -$428K | ﹤0.01% | 713 |
|
|
2014
Q3 | $380K | Buy |
5,262
+5,150
| +4,598% | +$338K | 0.02% | 381 |
|
|
2014
Q2 | $7K | Hold |
112
| – | – | ﹤0.01% | 850 |
|
|
2014
Q1 | $8K | Hold |
112
| – | – | ﹤0.01% | 830 |
|
|
2013
Q4 | $8K | Buy |
+112
| New | +$7.61K | ﹤0.01% | 815 |
|
Other funds holding BMRN
BBA
Compagnie Lombard Odier SCmA's BMRN Position: Q1 2022 in Review
Compagnie Lombard Odier SCmA sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 112 shares — an estimated $10K sold.
Compagnie Lombard Odier SCmA first reported a position in BMRN in Q4 2013 and held it in 33 quarters. The position peaked at $3.05M in Q2 2016. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.
- Compagnie Lombard Odier SCmA reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
- Compagnie Lombard Odier SCmA sold 112 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $10K.
- Compagnie Lombard Odier SCmA first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 33 quarters.
- Compagnie Lombard Odier SCmA's BioMarin Pharmaceuticals position peaked at $3.05M in Q2 2016.
- 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.
Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2022, filed 27 Apr 2022.